Clinical Trials Browser

Recruiting × cemiplimab × Endocrine × Clear all

Diabetes Mellitus, Insulin-Dependent, 12, Lethal Congenital Contracture Syndrome 2, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Multiple Endocrine Neoplasia Type 2a

NCT06900595 2026-04-14

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

Phase 2 Recruiting

48 enrolled

Endocrine

Adrenocortical Carcinoma

NCT06902376 2025-11-05

NEO-COMBATXL

Phase 1 Recruiting

12 enrolled

EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT07085572 2025-10-06

INTERVAL

Phase 2 Recruiting

31 enrolled

Endocrine

Adrenocortical Carcinoma

Clinical Trials

LuCa-MERIT-1

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

NEO-COMBATXL

INTERVAL